This page shows the latest Huntington's disease news and features for those working in and with pharma, biotech and healthcare.
Its Huntington’s disease candidate, currently known as AMT-130, becomes the first investigational AAV-gene therapy in this disease area to receive the status. ... UniQure ’s candidate fit the bill, not least because there are no currently approved
FDA grants orphan drug status to UniQure’ s Huntington’ s Disease treatment. ... Dutch biotech UniQure has won orphan drug designation (ODD) for its investigational treatment for Huntington’s Disease, a rare, inherited neurodegenerative disorder
The approval is the second for Austedo (deutetrabenazine) after being cleared by the US regulator for chorea - another movement disorder - in patients with Huntington's disease earlier this year. ... It is most commonly seen as a side effect of certain
The two companies have been collaborating on laquinimod since 2004, but insist they are still fully behind development of the drug for PPMS and Huntington's disease. ... Some 18 months ago Teva and Sweden's Active Biotech were forced to halt treatment
US approval for Austedo (deutetrabenazine) for movement symptoms associated with Huntington's disease, with a much smaller patient population. ... The COMT inhibitor was approved in Europe as Ongentys last June as an adjunct to Parkinson's disease
FDA approves Teva's Huntington's disease drug at second attempt. Austedo will treat fatal degenerative disorder chorea. ... The FDA approved Teva's treatment for symptoms associated with Huntington's disease (HD) yesterday, ending a decade-long drought
More from news
Approximately 4 fully matching, plus 28 partially matching documents found.
Teva's drug SD 809 for the treatment of Huntington's disease was part of the acquisition of Auspex at a cost of $3.5bn. ... disease late last year, Bayer announced another gene editing pact this month with ERS Genomics.
Voyager Therapeutics/ Sanofi (Genzyme). Gene therapy - Parkinson's disease, Friedreich's ataxia and Huntington's disease. ... Collaboration - discover, develop, commercialise. 450. Heptares Therapeutics/ Sosei Group . Novel G protein-coupled receptor
480. Isis Pharmaceuticals/ Roche. Collaboration. To develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology.
These deals, along with that announced with Moderna Therapeutics (messenger RNA therapies) and the purchase of AlphaCore (phase I programme for cardiovascular disease) earlier in the year exemplify AZ's focus ... Isis/ Roche. Isis, another biotech with a
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals. “ ... for congestive heart failure and Huntington's disease into the clinic.”.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Not only do they bring experience working on Rx accounts such as the immunology biosimilar portfolio for Novartis, but passion and expertise for animal health, disease awareness and charity work. ... 2016, Echoes of the past, Huntington's Disease (Teva).
pathway. When we think of biomarkers, we usually imagine the detection of genetic disorders such as Huntington’ s disease and Alzheimer’ s; these are prognosis biomarkers. ... A crowded market of biologics treating a chronic disease with very similar
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...